Condition: Crohn Disease · Sponsor: Hospices Civils de Lyon
This study aims to assess the prevalence of exocrine pancreatic insufficiency (EPI) in a population of patients with active Crohn's disease. Studies already describe a prevalence rate around 18-66%. In this multicentric prospective study, we plan to compare EPI's prevalence at week 0 and week 14 of an induction phase of a biological therapy. The biological therapy will be initiate for an active Crohn's disease. Secondary outcomes will be: malnutrition's prevalence, and Crohn's disease activity level.
This description comes directly from the study's public registry record.
Gilles BOSCHETTI, MD · 478860302 · gilles.boschetti@chu-lyon.fr
Charlotte BERGOIN, MD · 478863869 · charlotte.bergoin@chu-lyon.fr
Always discuss trial participation with your own doctor first.
| Service d'Hépato-Gastroentérologie, Centre Hospitalier Lyon-Sud, HCL | Pierre-Bénite, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03915262